The discovery of targetable mutations in genes other than EGFR and ALK, such as c-ros oncogene 1 (ROS1) and v-Raf murine sarcoma viral oncogene homolog B (BRAF) has led to the development of additional targeted therapies in NSCLC, specific to each genomic mutation [11]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.